Martin Phillips, MD

Dr. Martin Phillips is currently Co-Founder and CEO of Opsidio, a fibrosis-focused startup. In addition, Martin is also CEO of Tarnhelm Therapeutics, an Advisor to Integral Molecular, and on the Steering Committee of Mid-Atlantic BioAngels.  Martin brings nearly 30 years of experience including a career in academic medicine, biotech and the pharmaceutical industry. Previously, Martin served as the Chief Medical Officer at two venture-backed startups: Morphotek (acquired by Eisai), an antibody discovery platform; and a Millendo Therapeutics, a rare disease drug discovery company. Prior, Martin was VP of Clinical R&D at Aventis Behring, an Assistant Professor of Medicine at Baylor College of Medicine, and an Associate Professor at University of Texas-Houston.  He holds an M.D. from Wayne State University School of Medicine and a B.S. from the University of Michigan.

+ LinkedIn